SLS009 (GFH009)
Acute Myeloid Leukemia (AML)
Phase 1/2Active
Key Facts
About SELLAS Life Sciences
SELLAS Life Sciences is dedicated to advancing targeted immunotherapies for cancer, with a core focus on its WT1-targeting platform. Its most advanced candidate, galinpepimut-S, is in Phase 2/3 development for acute myeloid leukemia (AML) and malignant pleural mesothelioma. The company operates as a lean, clinical-stage organization, leveraging its expertise in antigen-specific vaccines to address significant unmet medical needs in oncology.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| NTLA-5001 | Intellia Therapeutics | Phase 1/2 |
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2/3 |
| UCART123 | Cellectis | Phase 1 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |
| MP0533 | Molecular Partners | Phase 1/2 |
| SEL24 (MEN1703) | Selvita | Phase 1/2 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| NEX-20 (azacitidine) | Nanexa AB | Phase 1 |
| SENTI-202 | Senti Biosciences | Phase 1 |
| motixafortide (BL-8040) | BioLineRx | Phase 2a |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |